Abvacc, Inc.
Rockville, MD
- UEI
- K5MSGRFGVVZ9
- CAGE
- 9FDC1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4 Research Ct #310, Rockville, MD 20850, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A multimodal approach for immunotherapy of staphylococcus aureus bacteremia - staphylococcus aureus (s. Aureus; SA)… | National Institute of Allergy and Infectious Diseases | $638,953 | |
| Development of a marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist | National Institute of Allergy and Infectious Diseases | $1,492,782 | |
| Monoclonal antibody cocktail for treatment of marburg virus disease - project summary ebola (ebov) and marburg (marv)… | National Institute of Allergy and Infectious Diseases | $2,586,781 | |
| Prophylactic immunotherapy for marburg virus disease outbreak control - the ebolaviruses (ebov, sudv, bdbv) and… | National Institute of Allergy and Infectious Diseases | $5,639,098 | |
| To develop a potent therapeutic marburgvirus monoclonal antibody. | National Institute of Allergy and Infectious Diseases | $3,467,335 |
About Abvacc, Inc.
Abvacc, Inc. is a for-profit biotechnology company located in Rockville, Maryland, specializing in the development of advanced medical countermeasures and immunotherapeutic solutions targeting critical infectious diseases. Registered in SAM.gov since December 2022, the company focuses on developing innovative therapeutic and prophylactic approaches for challenging viral pathogens, with a particular emphasis on emerging infectious diseases and biodefense applications. The company operates as a corporate entity and has demonstrated significant capabilities in monoclonal antibody research, vaccine development, and advanced immunological interventions.
Regarding federal contract awards, Abvacc, Inc. has secured a notable cost-plus-fixed-fee definitive contract from the National Institute of Allergy and Infectious Diseases (NIAID) valued at $16,927,478.76. This contract, awarded in May 2021, specifically targets the development of a potent therapeutic monoclonal antibody for Marburg virus. The contract, which runs through April 2025, was not set aside for any specific business category and will be executed in Potomac, Maryland. The award leverages NIAID's Omnibus Broad Agency Announcement and represents the company's capabilities in developing advanced medical countermeasures against high-risk pathogens.
In terms of federal grant awards, Abvacc, Inc. has received multiple project grants from NIAID focusing on critical infectious disease research. These grants include a $638,953 award to develop an immunotherapeutic antibody cocktail for Staphylococcus aureus bacteremia, a project running from August 2025 to July 2030. Additionally, the company has secured grants for developing Marburg virus subunit vaccines, including a project to create a vaccine adjuvanted with a novel TLR7/TLR8 agonist and another grant for developing a monoclonal antibody cocktail for Marburg virus disease treatment. The company has also received a grant focused on prophylactic immunotherapy for Marburg virus outbreak control and another addressing immunotherapy for MRSA osteomyelitis. These grants demonstrate Abvacc's expertise in developing advanced immunological interventions for complex infectious diseases, with a strong focus on creating novel therapeutic and preventive strategies.
Quick answers
What is Abvacc, Inc.'s UEI?
Abvacc, Inc.'s Unique Entity ID (UEI) in SAM.gov is K5MSGRFGVVZ9.
What is Abvacc, Inc.'s CAGE code?
Abvacc, Inc.'s CAGE code is 9FDC1.
What is Abvacc, Inc.'s primary NAICS code?
Abvacc, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Abvacc, Inc. located?
Abvacc, Inc.'s physical address in SAM.gov is 4 Research Ct #310, Rockville, MD 20850, USA.
Is Abvacc, Inc. registered in SAM.gov?
Yes. Abvacc, Inc.'s SAM.gov registration is active through September 15, 2027.
What is Abvacc, Inc.'s most recent federal award?
Abvacc, Inc.'s most recent federal grant award is A multimodal approach for immunotherapy of staphylococcus aureus bacteremia - staphylococcus aureus (s. Aureus; SA)… (R01AI193221), from National Institute of Allergy and Infectious Diseases, on August 22, 2025.
On GovTribe
See Abvacc, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors